Patents by Inventor Carl H. June

Carl H. June has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7754482
    Abstract: The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: July 13, 2010
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Carl H. June, Robert H. Vonderheide, Nicole Aqui, Megan M. Suhoski
  • Publication number: 20100061958
    Abstract: The present invention relates to compositions and methods for modulating the presence and/or activity of regulatory T cells in a subject.
    Type: Application
    Filed: September 14, 2007
    Publication date: March 11, 2010
    Inventors: Richard G. Carroll, Xiaochuan Shan, Gwenn-ael Danet-Desnoyers, Carl H. June
  • Publication number: 20090155836
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Application
    Filed: October 22, 2008
    Publication date: June 18, 2009
    Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, GENETICS INSTITUTE, LLC, The United States of America as Represented by the Secretary of the Navy
    Inventors: Carl H. JUNE, Craig B. THOMPSON, Gary J. NABEL, Gary S. GRAY, Paul D. RENNERT
  • Patent number: 7479269
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: January 20, 2009
    Assignees: Genetics Institute, LLC, Regents of the University of Michigan, The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
  • Publication number: 20080305092
    Abstract: The method of immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of activated T cell lymphokine production occurs upon stimulatory binding of the CD28 surface receptor molecule, even in the presence of conventional immunosuppressants. Inhibition of CD28 receptor binding to an appropriate stimulatory ligand or inactivation of the CD28 signal transduction pathway through other means down-regulates CD28-pathway related T cell lymphokine production and its resulting effects.
    Type: Application
    Filed: March 7, 2008
    Publication date: December 11, 2008
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Craig B. Thompson, Carl H. June
  • Patent number: 7232566
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: June 19, 2007
    Assignees: The United States as represented by the Secretary of the Navy, The Regents of the University of Michigan, Genetics Institute, LLC
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
  • Patent number: 7175843
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: February 13, 2007
    Assignees: Genetics Institute, LLC, Regents of the University of Michigan, The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
  • Patent number: 7172869
    Abstract: A method for transfecting T cells with a nucleic acid molecule comprising a gene such that the gene is expressed in the T cells is described. The T cells are stimulated and proliferating prior to introduction of the nucleic acid molecule.
    Type: Grant
    Filed: April 20, 2004
    Date of Patent: February 6, 2007
    Assignees: The United States of America as represented by the Secretary of the Navy, The Regents of the University of Michigan
    Inventors: Carl H. June, Thompson B. Craig, Suil Kim
  • Patent number: 7144575
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: December 5, 2006
    Assignees: The Regents of the University of Michigan, Genetics Institute, LLC, The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
  • Patent number: 7067318
    Abstract: A method for transfecting T cells with a nucleic acid molecule comprising a gene such that the gene is expressed in the T cells is described. The T cells are stimulated and proliferating prior to introduction of the nucleic acid molecule.
    Type: Grant
    Filed: September 9, 2003
    Date of Patent: June 27, 2006
    Assignees: The Regents of the University of Michigan, The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Craig B. Thompson, Suil Kim
  • Patent number: 6905680
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Grant
    Filed: January 26, 1996
    Date of Patent: June 14, 2005
    Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
  • Patent number: 6905681
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Grant
    Filed: July 8, 1999
    Date of Patent: June 14, 2005
    Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
  • Patent number: 6887466
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Grant
    Filed: July 8, 1999
    Date of Patent: May 3, 2005
    Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
  • Publication number: 20040203155
    Abstract: A method for transfecting T cells with a nucleic acid molecule comprising a gene such that the gene is expressed in the T cells is described. The T cells are stimulated and proliferating prior to introduction of the nucleic acid molecule.
    Type: Application
    Filed: April 20, 2004
    Publication date: October 14, 2004
    Applicants: The United States of America as Represented by the Secretary of the Navy, The Regents of the University of Michigan
    Inventors: Carl H. June, Craig B. Thompson, Suil Kim
  • Publication number: 20040185046
    Abstract: The method of immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of activated T cell lymphokine production occurs upon stimulatory binding of the CD28 surface receptor molecule, even in the presence of conventional immunosuppressants. Inhibition of CD28 receptor binding to an appropriate stimulatory ligand or inactivation of the CD28 signal transduction pathway through other means down-regulates CD28-pathway related T cell lymphokine production and its resulting effects.
    Type: Application
    Filed: November 14, 2003
    Publication date: September 23, 2004
    Inventors: Craig B. Thompson, Carl H. June
  • Publication number: 20040087025
    Abstract: A method for transfecting T cells with a nucleic acid molecule comprising a gene such that the gene is expressed in the T cells is described. The T cells are stimulated and proliferating prior to introduction of the nucleic acid molecule.
    Type: Application
    Filed: September 9, 2003
    Publication date: May 6, 2004
    Applicants: The United States of America as Represented by the Secretary of the Navy, The Regents of the University of Michigan
    Inventors: Carl H. June, Craig B. Thompson, Suil Kim
  • Publication number: 20040072766
    Abstract: Methods for modulating T cell responses by manipulating intracellular signals associated with T cell costimulation are disclosed. The methods involve inhibiting or stimulating the production of at least one D3-phosphoinositide in a T cell. Production of D3-phosphoinositides can be manipulated by contacting a T cell with an inhibitor or activator of phosphatidylinositol 3-kinase. Inhibitors of phosphatidylinositol 3-kinase for use in the methods of the invention include wortmannin and quercetin, or derivatives or analogues thereof. The methods of the invention can further comprise modulating other intracellular signals associated with costimulation, such as protein tyrosine phosphorylation, for example by modulating the activity of a protein tyrosine kinase or a protein tyrosine phosphatase in the T cell.
    Type: Application
    Filed: October 8, 2003
    Publication date: April 15, 2004
    Applicant: The United States of America as represented by the Secretary of Navy
    Inventor: Carl H. June
  • Patent number: 6692964
    Abstract: A method for transfecting T cells with a nucleic acid molecule comprising a gene such that the gene is expressed in the T cells is described. The T cells are stimulated and proliferating prior to introduction of the nucleic acid molecule.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 17, 2004
    Assignees: The United States of America as represented by the Secretary of the Navy, The Regents of the University of Michigan
    Inventors: Carl H. June, Craig B. Thompson, Suil Kim
  • Patent number: 6685941
    Abstract: The method of immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of activated T cell lymphokine production occurs upon stimulatory binding of the CD28 surface receptor molecule, even in the presence of conventional immunosuppressants. Inhibition of CD28 receptor binding to an appropriate stimulatory ligand or inactivation of the CD28 signal transduction pathway through other means down-regulates CD28-pathway related T cell lymphokine production and its resulting effects.
    Type: Grant
    Filed: February 7, 1995
    Date of Patent: February 3, 2004
    Assignees: The Regents of the University of Michigan, The United States of America as represented by the Secretary of the Navy
    Inventors: Craig B. Thompson, Carl H. June
  • Publication number: 20040001829
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Application
    Filed: March 17, 2003
    Publication date: January 1, 2004
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert